KEGG   DRUG: Anifrolumab
Entry
D11082                      Drug                                   
Name
Anifrolumab (USAN);
Anifrolumab (genetical recombination) (JAN);
Anifrolumab-fnia;
Saphnelo (TN)
Product
Formula
C6444H9964N1712O2018S44
Exact mass
145027.7401
Mol weight
145117.1846
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGESLKI SCKGSGYIFT NYWIAWVRQM PGKGLESMGI IYPGDSDIRY
SPSFQGQVTI SADKSITTAY LQWSSLKASD TAMYYCARHD IEGFDYWGRG TLVTVSSAST
KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APEFEGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA SIEKTISKAK GQPREPQVYT LPPSREEMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Lihgt chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFFAWYQQK PGQAPRLLIY GASSRATGIP
DRLSGSGSGT DFTLTITRLE PEDFAVYYCQ QYDSSAITFG QGTRLEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-96, H144-H200, H220-L215, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'144-H'200, H'220-L'215, H'261-H'321, H'367-H'425, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  Type
Peptide
Remark
Therapeutic category: 3999
ATC code: L04AA51
Product: D11082<JP/US>
Efficacy
Immunomodulator, Anti-IFN-type 1 receptor antibody
  Disease
Systemic lupus erythematosus [DS:H00080]
Comment
Monoclonal antibody
Treatment of systemic lupus erythematosus (SLE)
Target
IFNAR1 [HSA:3454] [KO:K05130]
IFNAR2 [HSA:3455] [KO:K05131]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA51 Anifrolumab
      D11082  Anifrolumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Immunological Agents, Miscellaneous
    Anifrolumab
     D11082  Anifrolumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D11082  Anifrolumab (USAN); Anifrolumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interferon receptors
    IFNAR1
     D11082  Anifrolumab (USAN) <JP/US>
    IFNAR2
     D11082  Anifrolumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11082
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11082
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11082
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11082
Other DBs
CAS: 1326232-46-5
PubChem: 375581029
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system